Last reviewed · How we verify
ABCD
ABCD is an investigational drug in phase 3 development by CSPC Ouyi Pharmaceutical Co., Ltd., but its specific mechanism of action is not publicly disclosed.
At a glance
| Generic name | ABCD |
|---|---|
| Sponsor | CSPC Ouyi Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without access to detailed clinical trial data or published literature on this specific investigational compound, the precise molecular mechanism cannot be reliably determined. Phase 3 status indicates it has progressed through earlier safety and efficacy testing, but the mechanism remains proprietary or undisclosed.
Approved indications
Common side effects
Key clinical trials
- A Relative Bioavailability Study of Nicotine Delivery From Selected Oral Nicotine Products (NA)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction
- Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore (NA)
- Visual Outcomes and Quality of Life After Vivity EDOF IOL Implantation in Early-Stage Keratoconus (NA)
- Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal or Dorsogluteal) and the Use or Non-use of Virtual Reality Headset (NA)
- Relative Bioavailability of Evobrutinib Tablet Batches (PHASE1)
- A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |